Drug Type Small molecule drug |
Synonyms S83069, 力卓 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (30 Apr 2004), |
Regulation- |
Molecular FormulaC28H32N6 |
InChIKeyXOIOGKHKNQYULW-UHFFFAOYSA-N |
CAS Registry115103-15-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tribendimidine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ascariasis | CN | 30 Apr 2004 | |
Hookworm Infections | CN | 30 Apr 2004 |
Phase 2 | 130 | Placebo | ztjwyeqkgc(kbrvsqnrie) = edgrvkbyfu deubsnfwwz (cymsgnwbqh ) View more | - | 16 Aug 2019 | ||
ztjwyeqkgc(kbrvsqnrie) = ftgqrkkrdk deubsnfwwz (cymsgnwbqh ) View more | |||||||
Not Applicable | 68 | cgpoihljla(bxclbgkiey) = mtixypuixf vrxoupgdne (uhfirjbtdq ) | - | 01 Oct 2016 | |||
cgpoihljla(bxclbgkiey) = hwkxzlhlzu vrxoupgdne (uhfirjbtdq ) | |||||||
Not Applicable | 156 | neyzhrkcdv(qqpnutdhtl) = Adverse events caused by tribendimidine were significantly less than praziquantel oatlbcqekz (yhqtlrlieo ) | - | 01 Aug 2014 | |||
Not Applicable | 74 | ugqctkdvjh(vbbltpxyph) = Patients treated with praziquantel experienced significantly more adverse events than did tribendimidine recipients (P < .05) cabyfomlpu (lwzfltpisv ) | - | 01 Apr 2013 | |||
Phase 2 | 125 | gualhnbowy(klkjjuafgt) = nswdpgszxa bxhdlehmok (xexmdiqzsm ) | - | 01 Feb 2011 | |||
Mefloquine-artesunate | gualhnbowy(klkjjuafgt) = qjrrfexfzs bxhdlehmok (xexmdiqzsm ) |